New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 19, 2012
10:52 EDTAMRN, GSKFish oil market may be bigger challenge than patents for Amarin, Forbes says
Scientific publications, doctors' commentary, and prescription trends all hint that the U.S. market for prescription fish oil may be shifting dramatically, which could be a bigger problem for Amarin (AMRN) than patent protection for its Vascepa drug, according to Forbes. Use of GlaxoSmithKline's (GSK)Lovaza, an alternative treatment, has declined, the report added. Reference Link
News For AMRN;GSK From The Last 14 Days
Check below for free stories on AMRN;GSK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for AMRN;GSK

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use